ReviewCrohn's & colitis 3602026
Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.
Review in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and Purpose: Inflammatory bowel disease (IBD) care is moving from a symptom-driven step-up model of care toward earlier effective intervention, complication-specific management, and more personalized treatment selection. This review synthesizes selected ECCO 2026 studies and offers an expert appraisal of their clinical relevance, methodological strengths, and remaining uncertainties. Particular emphasis is placed on studies most likely to influence current practice and further research, including late-breaking trials, complication-directed therapy, pediatric evidence, and technology-assisted assessment. Summary of Findings: Study findings spanned both ulcerative colitis (UC) and Crohn's disease (CD). New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric UC, phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal CD. Real-world data presented included comparative data on different Janus kinase inhibitors in UC. Updates on interleukin-23 included durable extension data in UC, as well as efficacy data in advanced therapy‑exposed patients (mirikizumab in UC and risankizumab in CD). Innovative technologies included transperineal ultrasound for early identification of steroid non-response in acute severe UC, and multimodal artificial intelligence for Mayo endoscopic scoring. Beyond drug therapy, the 10-year LIR! C follow-up provided further data on surgical intervention as an early strategy in selected uncomplicated ileal CD, while the Preventing IBD ONset in Individuals at Risk study investigated potential benefits of a whole-food diet in high-risk first-degree relatives. Conclusion and Next Steps: ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled IBD care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.